Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
Status:
Terminated
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in
patients with metastatic androgen independent prostate cancer where efficacy is measured by
PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at
least 4 weeks apart.